Form 4: ANI Pharma GC Cook Acquires Shares, Sells for Tax

ANI Pharmaceuticals' Senior VP, General Counsel & Secretary, Meredith Cook, reported the acquisition of 13,895 restricted stock units and the sale of 1,555 shares for tax purposes.

Summary

• Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., acquired 13,895 shares of common stock on February 26, 2026, at a price of $77.15 per share.
• This acquisition represents a restricted stock award that will vest in four equal annual installments starting February 26, 2027.
• Following this transaction, Cook beneficially owned 81,445 shares directly.
• On February 28, 2026, Cook disposed of 1,555 shares of common stock at $73.9 per share.
• These shares were withheld for tax purposes in connection with the vesting of 3,040 previously reported restricted stock shares.
• After the tax-related disposition, Cook's direct beneficial ownership stands at 79,890 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily reflecting routine executive compensation and tax-related transactions. The significant restricted stock award indicates continued commitment and incentive alignment for a key executive.

Positives

• Meredith Cook received a significant restricted stock award of 13,895 shares, indicating continued compensation and alignment of interests with shareholders.
• The acquisition price of $77.15 per share for the restricted stock award is a positive indicator of the company's valuation at the time of grant.

Negatives

• The disposition of 1,555 shares for tax purposes, while a common practice, reduces the direct beneficial ownership by that amount.
• The sale price of $73.9 per share for the tax-related disposition is lower than the acquisition price of the new restricted stock award ($77.15), though these are separate events.

Future Outlook

The restricted stock award vesting schedule indicates a long-term incentive structure for Meredith Cook, with shares vesting annually over four years from February 26, 2026.

Industry Context

StockSavvy.ai notes that insider transactions, particularly restricted stock awards, are common forms of executive compensation in the pharmaceutical industry, aligning management incentives with long-term shareholder value. The tax-related disposition is a routine event associated with the vesting of such awards.

Comparison to Industry Standards

• This Form 4 filing details standard executive compensation practices within the pharmaceutical sector. Restricted stock awards are a prevalent mechanism used by companies like Pfizer, Merck, and Johnson & Johnson to incentivize long-term performance and retain key executives.
• The tax withholding upon vesting is also a standard procedure across industries, including tech (e.g., Apple, Microsoft) and finance (e.g., JPMorgan Chase), to cover statutory tax obligations.

Stakeholder Impact

• Shareholders: The restricted stock award aligns the interests of a key executive with shareholders, potentially encouraging long-term value creation. The tax-related sale is a minor, routine event.
• Employees: This filing pertains specifically to a senior executive's compensation and does not directly impact the broader employee base.

Next Steps

• The acquired restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation. While the acquisition of restricted stock is a positive sign of executive alignment, the overall impact on the company's fundamentals or strategic direction is minimal. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

ANI Pharmaceuticals, ANIP, Meredith Cook, Insider Trading, Form 4, Restricted Stock, Stock Award, Executive Compensation, Share Acquisition, Tax Withholding